April 3, 2017 09:27 AM EDT
Financing

Armed with deals, dol­lars and the promise of up­com­ing da­ta, Zymeworks files $75M IPO

John Carroll

Editor & Founder

A lit­tle more than a year ago, as Zymeworks CEO Ali Tehrani was reel­ing in a $61.5 mil­lion crossover round, the biotech CEO

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

TRENDING NOW

Re­searchers make case against Gilead in HIV prod­uct hop­ping fight

Viking Ther­a­peu­tics taps Cor­den­Phar­ma to man­u­fac­ture its obe­si­ty drugs

Mallinck­rodt and En­do ex­plor­ing a $7B merg­er — re­port

Up­dat­ed: Zealand part­ners with Roche on its amylin ana­log in a deal worth up to $5.3B

Ono li­cens­es rare blood dis­ease drug from Io­n­is for $280M up­front

sponsored

Obe­si­ty drug de­vel­op­ment—still room to grow

A service from the Financial Times